Effects of Neoadjuvant Combined Chemotherapy and Radiation Therapy on the CT Evaluation of Resectability and Staging in Patients with Pancreatic Head Cancer
Authors:
- Mi-Suk ParkMPMi-Suk Park
- Hye-Suk HongHHHye-Suk Hong
- Chang Moo KangCKChang Moo Kang
- Jin-Young ChoiJCJin-Young Choi
- Joon Seok LimJLJoon Seok Lim
- Woo Jung LeeWLWoo Jung Lee
- Myeong-Jin KimMKMyeong-Jin Kim
- Ki Whang KimKKKi Whang Kim
- 1 March 2009
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 250 (3) , 758-765
Abstract
To evaluate the effect of neoadjuvant combined chemotherapy and radiation therapy (CCRT) on preoperative accuracy of multidetector computed tomography (CT) for resectability and tumor staging in patients with pancreatic head cancer. This retrospective study received institutional review board approval and was exempted from informed consent requirements. From May 2002 to March 2007, 38 patients with pancreatic head adenocarcinoma underwent multidetector CT before surgery. Of these, 12 patients received neoadjuvant CCRT. Imaging findings were evaluated for tumor resectability and tumor staging. Surgical and pathologic results were used as the reference standard. The accuracy of resectability and individual components of each T category were compared between the patients with neoadjuvant CCRT and without it by using the chi(2) test or Fisher exact test. A P of less than .05 was considered as significant. The accuracy in determining resectability was 83% (10 of 12) in patients who had received neoadjuvant CCRT and 81% (21 of 26) in patients who had not, without significant difference (P > .05). Of 32 patients who underwent pancreaticoduodenectomy, histopathologic tumor staging was reported for T1 (n = 2), T2 (n = 1), and T3 (n = 9) lesions in patents with neoadjuvant CCRT (n = 12), and for T3 in all patients without neoadjuvant CCRT (n = 20). T-staging accuracy was 67% (eight of 12) with neoadjuvant CCRT and 95% (19 of 20) without it, with a significant difference (P = .0185). Neoadjuvant CCRT reduces the accuracy of tumor restaging after treatment of pancreatic head cancer, but this effect is not so great as to affect the determination of resectability.Keywords
This publication has 22 references indexed in Scilit:
- Resectability of pancreatic adenocarcinoma: assessment using multidetector-row computed tomography with multiplanar reformationsAbdominal Radiology, 2007
- Pancreatic Duodenal Homeobox 1 Expression Is Insufficient to Transdifferentiate Liver Cells Into Insulin-Secreting CellsPancreas, 2007
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006
- Venous resection in pancreatic cancer surgeryBest Practice & Research Clinical Gastroenterology, 2006
- Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experienceJournal of Gastrointestinal Surgery, 2004
- Dual-Phase Helical CT of Pancreatic AdenocarcinomaAmerican Journal of Roentgenology, 2002
- Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the PancreasAnnals of Surgical Oncology, 2001
- Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim RealityAnnals of Surgical Oncology, 2001
- TNM staging of pancreatic carcinoma using helical CT.American Journal of Roentgenology, 1997